Quel est le prix pour Entropy Neurodynamics Limited (ENP)

Le prix pour Entropy Neurodynamics Limited (ENP) est $0.02468497

Quelle est la capitalisation boursière pour Entropy Neurodynamics Limited (ENP)

La capitalisation boursière pour Entropy Neurodynamics Limited (ENP) est $40.28M

Entropy Neurodynamics Limited (ENP) Historique des Prix

Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.

Année	Performance
2026 (TTM)	14.81%
2025	0.00%

Année

Performance

2026 (TTM)

14.81%

2025

0.00%

Entreprise	Prix de l'action	Variation 1a%	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	$546.54	38.59%	US
Argenx SE ARGX.US	$1.04K	56.71%	NL
CSL Limited CSL.AX	$120.74	-14.98%	AU
Moderna, Inc. MRNA.US	$138.98	416.85%	US
Lonza Group AG LONN.SW	$761.87	7.04%	CH

Entreprise

Prix de l'action

Variation 1a%

Pays